Cargando…

Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death

Dasatinib and radotinib are oral BCR-ABL tyrosine kinase inhibitors that were developed as drugs for the treatment of chronic myeloid leukemia. We report here that the c-KIT (CD117) targeting with dasatinib and radotinib promotes acute myeloid leukemia (AML) cell death, and c-KIT endocytosis is esse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heo, Sook-Kyoung, Noh, Eui-Kyu, Kim, Jeong Yi, Jeong, Yoo Kyung, Jo, Jae-Cheol, Choi, Yunsuk, Koh, SuJin, Baek, Jin Ho, Min, Young Joo, Kim, Hawk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681687/ https://www.ncbi.nlm.nih.gov/pubmed/29127384 http://dx.doi.org/10.1038/s41598-017-15492-5

Ejemplares similares

Author Correction: Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2015)

Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
por: Heo, Sook-Kyoung, et al.
Publicado: (2022)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity
por: Heo, Sook-Kyoung, et al.
Publicado: (2014)

LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2016)

CD45(dim)CD34(+)CD38(−)CD133(+) cells have the potential as leukemic stem cells in acute myeloid leukemia
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease
por: Choi, Yeong-Gon, et al.
Publicado: (2023)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
por: Kim, Kyung Eun, et al.
Publicado: (2018)

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
por: Do, Young Rok, et al.
Publicado: (2020)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)

The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation
por: Heo, Sook-Kyoung, et al.
Publicado: (2022)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
por: Lee, Saebom, et al.
Publicado: (2018)

Radotinib attenuates TGFβ -mediated pulmonary fibrosis in vitro and in vivo: exploring the potential of drug repurposing
por: Baek, Suji, et al.
Publicado: (2022)

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015)

Novel FIP1L1::KIT fusion in a myeloid neoplasm with eosinophilia, T-lymphoblastic transformation, and dasatinib response
por: Alsouqi, Aseel, et al.
Publicado: (2023)

LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
por: Kim, Yu Jin, et al.
Publicado: (2016)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Evaluation of the Expression of C-kit (CD117) in Ependymomas and Oligodendrogliomas
por: Zavalhia, Lisiane Silveira, et al.
Publicado: (2012)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review
por: Kim, Sang-A, et al.
Publicado: (2022)

Erratum to “Evaluation of the Expression of C-Kit (CD117) in Ependymomas and Oligodendrogliomas”
por: Zavalhia, Lisiane Silveira, et al.
Publicado: (2014)

KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
por: Nishida, Haruto, et al.
Publicado: (2015)

LIGHT (TNFSF14) promotes the differentiation of human bone marrow-derived mesenchymal stem cells into functional hepatocyte-like cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2023)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Synchronous development of KIT positive acute myeloid leukemia in a patient with gastrointestinal stromal tumor
por: Joo, Young-Bin, et al.
Publicado: (2010)

Correlation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients
por: El-Meligui, Yomna M, et al.
Publicado: (2021)

Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometry
por: Seo, Hyo-Bum, et al.
Publicado: (2017)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy
por: Jin, Wenying, et al.
Publicado: (2022)

Evaluation of c-kit protein (CD117) expression in common salivary gland neoplasms
por: Salehinejad, Jahanshah, et al.
Publicado: (2014)

CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
por: Foster, Brittni M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i2sqo35qbrgblmud7m4kbag74d